Suzhou Fengbei Biotech Stock Co (SHSE:603334) EBIT: ¥167 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:603334 Suzhou Fengbei Biotech Stock Co Ltd SHSE:603334
40 GF Score
Price ¥32.07
! 4 Warning Signs
View Full Analysis

What is Suzhou Fengbei Biotech Stock Co EBIT?

Suzhou Fengbei Biotech Stock Co SHSE:603334 +0.88% 40 EBIT is ¥167 Mil as of Mar. 2026. GuruFocus rates SHSE:603334 with a GF Score™ of 40/100. The stock has 4 warning signs investors should review.

Suzhou Fengbei Biotech Stock Co's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2026 was ¥46 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was ¥167 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Suzhou Fengbei Biotech Stock Co's annualized ROC % for the quarter that ended in Mar. 2026 was 14.64%. Suzhou Fengbei Biotech Stock Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 20.44%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Suzhou Fengbei Biotech Stock Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 4.31%.

Suzhou Fengbei Biotech Stock Co  (SHSE:603334) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Suzhou Fengbei Biotech Stock Co's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

ROC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=191.872 * ( 1 - 10.75% )/( (1153.97 + 1185.196)/ 2 )
=171.24576/1169.583
=14.64 %

where

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=2225.344 - 204.075 - ( 867.299 - max(0, 491.816 - 1727.283+867.299))
=1153.97

Invested Capital(Q: Mar. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=2166.451 - 188.673 - ( 792.582 - max(0, 414.064 - 1669.977+792.582))
=1185.196

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

Suzhou Fengbei Biotech Stock Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=185.916/( ( (416.882 + max(508.048, 0)) + (414.473 + max(479.802, 0)) )/ 2 )
=185.916/( ( 924.93 + 894.275 )/ 2 )
=185.916/909.6025
=20.44 %

where Working Capital is:

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(172.586 + 522.602 + 75.82) - (204.075 + 0 + 58.885)
=508.048

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(146.04 + 453.658 + 170.138) - (188.673 + 0 + 101.361)
=479.802

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Suzhou Fengbei Biotech Stock Co's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2026 )
=166.594/3861.362
=4.31 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Suzhou Fengbei Biotech Stock Co EBIT Related Terms

Suzhou Fengbei Biotech Stock Co EBIT Historical Data

* Premium members only.

The historical data trend for Suzhou Fengbei Biotech Stock Co's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Suzhou Fengbei Biotech Stock Co EBIT Chart

Suzhou Fengbei Biotech Stock Co Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBIT
Get a 7-Day Free Trial 111.77 162.31 158.64 146.42 161.19

Suzhou Fengbei Biotech Stock Co Quarterly Data
Dec20 Dec21 Dec22 Dec23 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 41.08 55.87 35.58 28.66 46.48

SHSE:603334 vs WM, RSG, WCN: EBIT Comparison

For the Waste Management subindustry, Suzhou Fengbei Biotech Stock Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Suzhou Fengbei Biotech Stock Co EV-to-EBIT vs Waste Management Industry

For the Waste Management industry and Industrials sector, Suzhou Fengbei Biotech Stock Co's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Suzhou Fengbei Biotech Stock Co's EV-to-EBIT falls into.


SHSE:603334
40GF Score
Suzhou Fengbei Biotech Stock Co Ltd SHSE:603334
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Suzhou Fengbei Biotech Stock Co EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥167 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of ¥167 Mil mean?
Suzhou Fengbei Biotech Stock Co (SHSE:603334) has a EBIT of ¥167 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Suzhou Fengbei Biotech Stock Co.
Is Suzhou Fengbei Biotech Stock Co's EBIT too high?
Suzhou Fengbei Biotech Stock Co's current EBIT is ¥167 Mil. Overall, Suzhou Fengbei Biotech Stock Co has a GF Score™ of 40/100, reflecting its overall financial health beyond just this single metric.
How does Suzhou Fengbei Biotech Stock Co's EBIT compare to WM and RSG?
Suzhou Fengbei Biotech Stock Co's EBIT of ¥167 Mil can be compared against companies in the Waste Management industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Waste Management company?
A good EBIT depends on the Waste Management industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Suzhou Fengbei Biotech Stock Co. Suzhou Fengbei Biotech Stock Co's current EBIT is ¥167 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Suzhou Fengbei Biotech Stock Co stock overvalued right now?
Suzhou Fengbei Biotech Stock Co (SHSE:603334) has a current EBIT of ¥167 Mil. The current EBIT is ¥167 Mil. Suzhou Fengbei Biotech Stock Co's overall GF Score™ is 40/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Suzhou Fengbei Biotech Stock Co (SHSE:603334), the current EBIT is ¥167 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Suzhou Fengbei Biotech Stock Co Business Description

Address No. 1 Donghai Road, Yangtze River International Chemical Industrial Park, Jiangsu Province, Zhangjiagang, CHN, 215600
Suzhou Fengbei Biotech Stock Co Ltd is focused on the comprehensive utilization of waste oil and fat resources. The company is engaged in the research and development, production, and sales of industrial packaging materials, methyl oleate, and methylated soybean oil (excluding food products). It operates as an independent import and export agent for various commodities and technologies. The company's licensed projects include Fertilizer production, and General projects include Technical services, technical development, technical consultation, technical exchange, technology transfer, and technology promotion. It is into the research and development of bio-organic fertilizers, compound microbial fertilizers, and bio-pesticide technology.
40GF Score

Get the complete analysis for SHSE:603334

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥32.07
Price